Osimertinib improves progression-free survival in Asian EGFR-mutated lung cancer patients
LUGANO, 20 November 2017 - Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according...





